Prevention of bone metastases in breast cancer
https://doi.org/10.17650/1994-4098-2010-0-3-24-26
Abstract
The paper deals with the prevention of bone metastases in patients with breast cancer (BC). The drugs from a group of bisphosphonates are ascertained to play an important role in combination therapy for bone metastases. Bonefos (clodronate) is one of these agents used in BC patients for prophylaxis.
References
1. Green J.R., Muller K., Jaeggi K.A. et al. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745–51.
2. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165–76.
3. Plosker G.L., Goa K.L. Clodronate. Drugs 1994;47:221–6.
4. Adami S., Mian M. Clodronate therapy of mts bone disease in patients with prostatic carcinoma. Cancer Res 1989;116:67–72.
5. Paterson A.H.G., Powles T.J., Kanis J.A. et al. Double-blind controlled trial of oral clodronate in patients with bone mts from breast cancer. J Clin Oncol 1993;11:59–65.
6. Powles T.J., Paterson S., Kanis J.A. et al. Randomised, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002;20:3219–24.
7. Coleman R.E., Rubens R.D. The clinical course of bone mts from brest cancer. Br J Cancer 1987;55:61–6.
8. Стенина М.Б. Зомета®: взгляд в будущее. Мед вестн 2008;27(454).
Review
For citations:
Kogonia L.M. Prevention of bone metastases in breast cancer. Tumors of female reproductive system. 2010;(3):24-26. (In Russ.) https://doi.org/10.17650/1994-4098-2010-0-3-24-26
Views:
533
Email this article 